Back to results
US 12,280,095 B2Granted
Tissue modifier and uses therefor
AssigneeFibrosoft Pte Ltd
InventorDavid Chin
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions, methods, uses, kits and articles of manufacture, which are based on the use of a hyaluronidase and a collagen-reducing agent, for reducing or inhibiting the development of fibrosis in a tissue, or for treating collagen-mediated disorders. In specific embodiments, the collagen-mediated disorders are fibroproliferative disorders involving alterations of collagen, including fibromatoses such as Dupuytren's disease. Peyronie's disease and Ledderhose's disease.
Claims26
A pharmaceutical composition comprising:
- a plasminogen activator in an amount of 1 mg to 50 mg per single unit dose, wherein the plasminogen activator is selected from saruplase, alteplase, reteplase, tenecteplase, anistreplase, monteplase and lanoteplase;
- and
- a hyaluronidase in amount of 0.4 mg to 2 mg per single unit dose, wherein the hyaluronidase is selected from Amphadase, Hyalase, Hydase, Hylase, rHuPH20/Hylenex, Vitrase, and Wydase.
A pharmaceutical composition comprising:
- alteplase in an amount of 1 mg to 50 mg per single unit dose;
- and
- Hyalase in amount of from 0.4 mg to 2 mg per single unit dose.
Dependencies are inferred from the claim text.